Subclassification of Hodgkin's disease, nodular sclerosis type. Prognostic value?
Recently, studies have suggested a subclassification of Hodgkin's disease, nodular sclerosis (HDNS). Between 1985-1994, twenty-four patients with HDNS were treated at the University Hospital of Tromsø, Norway. The cases were subclassified according to the histological criteria from the British National Lymphoma Investigation (BNLI) into NS1 (15 patients) and NS2 (9 patients). The relative frequencies of the two subtypes of HDNS in our region were in agreement with other reports. After a median follow up of 33 months, no significant difference between NS1 and NS2 with regard to complete remission rate (87% versus 100%) or predicted 5-year actuarial survival (93% versus 75%) were observed. Although our data are too small to draw specific conclusions, the discrepancy with some of the previous studies could be due to an improved response of the more aggressive type (NS2) to optimal treatment. We hope this study may initiate a raised interest in this field.